Skip to main content

Apnimed Inc.

corporate_fare Company Profile

Apnimed Inc.

APMD·NASDAQ·Life Sciences·CIK 0001745648

Apnimed Inc. is a clinical pharmaceutical company that develops and manufactures novel oral therapies addressing the neurobiology of sleep-related breathing diseases in global markets. The company's primary product is AD109, an oral therapy specifically designed to treat obstructive sleep apnea (OSA). AD109 targets the underlying neuromuscular dysfunction associated with OSA. Apnimed Inc. was incorporated in 2017 and operates from its base in Cambridge, Massachusetts.

Apnimed Inc. (NASDAQ:APMD) is a publicly traded company in the Life Sciences sector. Wiseek monitors APMD SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Apnimed IPO Prices at $16 High End, Upsized to $192M, Shares Jump
$23.03
Live data · 2026-07-31 19:07 UTC · Market open

show_chartPrice Chart

Loading chart...

feed APMD - Latest Insights

APMD
Jul 31, 2026, 12:44 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Apnimed IPO Prices at $16 High End, Upsized to $192M, Shares Jump
Price at Filing: $18.95
Real-time Price: $23.03 info
Change: +$4.08 (+22%) info
Market Cap: N/A info
Sentiment: Positive
View Wiseek Article